Immunic (NASDAQ:IMUX) Downgraded by Zacks Research to "Hold"

Immunic (NASDAQ:IMUX - Get Free Report) was downgraded by equities research analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research note issued to investors on Tuesday, Zacks reports.

Several other research analysts also recently issued reports on IMUX. Wedbush reaffirmed an "outperform" rating and issued a $45.00 price objective on shares of Immunic in a research note on Thursday, September 10th. HC Wainwright reiterated a "buy" rating and set a $22.00 target price on shares of Immunic in a research report on Thursday, September 10th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immunic in a research report on Wednesday, August 26th. Cantor Fitzgerald began coverage on shares of Immunic in a research report on Friday, October 23rd. They issued an "overweight" rating for the company. Finally, Roth Capital restated a "buy" rating on shares of Immunic in a research report on Tuesday, September 1st. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $35.43.

Immunic Stock Up 1.0%

Shares of IMUX opened at $8.12 on Tuesday. Immunic has a 12-month low of $5.06 and a 12-month high of $17.43. The business has a 50-day simple moving average of $8.93 and a two-hundred day simple moving average of $11.51. The stock has a market cap of $110.79 million, a PE ratio of -1.85 and a beta of 1.48.

Immunic (NASDAQ:IMUX - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.36. On average, equities research analysts expect that Immunic will post -3.69 EPS for the current year.

Institutional Investors Weigh In On Immunic

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Aberdeen Group plc lifted its stake in shares of Immunic by 32.3% in the third quarter. Aberdeen Group plc now owns 1,090,427 shares of the company's stock worth $10,141,000 after acquiring an additional 266,034 shares during the period. Alps Advisors Inc. boosted its holdings in Immunic by 28.0% in the third quarter. Alps Advisors Inc. now owns 17,694 shares of the company's stock valued at $165,000 after acquiring an additional 3,870 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Immunic by 21.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company's stock valued at $69,000 after purchasing an additional 1,400 shares during the period. Braidwell LP acquired a new stake in Immunic during the 2nd quarter valued at approximately $9,914,000. Finally, Avidity Partners Management LP increased its position in Immunic by 42.6% during the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company's stock valued at $7,436,000 after purchasing an additional 2,000,000 shares during the period. Institutional investors and hedge funds own 51.82% of the company's stock.

About Immunic

Immunic, Inc. NASDAQ: IMUX is a clinical-stage biopharmaceutical company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on treatments designed to address significant unmet needs while potentially offering convenient alternatives to injectable or infusion-based therapies. Immunic's lead product candidate is vidofludimus calcium, formerly known as IMU-838. It is a selective oral inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for multiple sclerosis, including relapsing and progressive forms of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.